AddedRisk Factors
Our equity interests in any such subsidiary would rank behind all of the secured and unsecured creditors, known or unknown, of such subsidiary, including the lenders in any credit facility. Consequently, to the extent that the value of such subsidiary’s portfolio of loan investments would have been reduced as a result of conditions in the credit markets, defaulted loans, capital gains and losses on the underlying assets, prepayment or changes in interest rates, the return on our investment in such subsidiary could be reduced. Accordingly, our investment in such subsidiary may be subject to up to a complete loss.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedRisk Factors
Our ability to sell investments held by any subsidiary that enters into a credit facility would be limited.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedRisk Factors
The MUFG Bank Facility places significant restrictions on our ability, as servicer, to sell investments, and we expect that any credit facility we enter into in the future would include similar restrictions. As a result, there may be times or circumstances during which we would be unable to sell investments or take other actions that might be in our best interests.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedRisk Factors
allocating investment opportunities between us, the Adviser Funds and External Parties managed by the Adviser Subsidiary.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RemovedRisk Factors
Development” industry,16.7% comprised investments in the “Healthcare Services, Other” industry, and 10.2% in the “Consumer & Business Services industry”. Companies in technology-related industries are subject to numerous risks, including:
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedRisk Factors
assurance that adequate third-party coverage will be available for pharmaceutical companies to obtain satisfactory price levels for their products.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedRisk Factors
•Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system disorders for which there are limited treatment options.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedRisk Factors
•Corium, Inc. develops, engineers, and manufactures drug delivery products and devices that utilize the skin and mucosa as a primary means of transport.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedRisk Factors
common stock, the percentage ownership of our stockholders at that time would decrease, and they may experience dilution. Moreover, we can offer no assurance that we will be able to issue and sell additional equity securities in the future, on favorable terms or at all.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedRisk Factors
We may in the future determine to issue preferred stock, which could adversely affect the market value of our common stock.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedRisk Factors
The issuance of shares of preferred stock with dividend or conversion rights, liquidation preferences or other economic terms favorable to the holders of preferred stock could adversely affect the market price for our common stock by making an investment in the common stock less attractive. In addition, the dividends on any preferred stock we issue must be cumulative. Payment of dividends and repayment of the liquidation preference of preferred stock must take preference over any dividends or other payments to our common stockholders, and holders of preferred stock are not subject to any of our expenses or losses and are not entitled to participate in any income or appreciation in excess of their stated preference (other than convertible preferred stock that converts into common stock). In addition, under the 1940 Act, preferred stock constitutes a “senior security” for purposes of the asset coverage test.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedRisk Factors
The agreements governing our indebtedness, including our Notes and Credit Facilities, require us to comply with certain financial, operational and payment covenants. These covenants require us to, among other things, maintain certain financial ratios, including asset coverage, debt to equity and interest coverage. Our ability to continue to comply with these covenants in the future depends on many factors, some of which are beyond our control. Any default under such
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedRisk Factors
There is significant uncertainty with respect to legislation, regulation and government policy at the federal level, as well as the state and local levels. Recent events, including the 2024 U.S. presidential election, have created a climate of heightened uncertainty and introduced new and difficult-to-quantify macroeconomic and political risks with potentially far-
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedRisk Factors
reaching implications. To the extent the U.S. Congress or the presidential administration implements changes to U.S. policy, those changes may impact, among other things, the U.S. and global economy, international trade and relations, unemployment, immigration, corporate taxes, healthcare, the U.S. regulatory environment, inflation and other areas. Although we cannot predict the impact, if any, of these changes to our business, they could adversely affect our business, financial condition, operating results and cash flows. Until we know what policy changes are made and how those changes impact our business and the business of our competitors over the long term, we will not know if, overall, we will benefit from them or be negatively affected by them.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RewordedRisk Factors
As of December 31, 2024, 2025, approximately 85.9% 87.1% of the fair value of our portfolio comprised investments in four five industries: 29.5% 24.3% comprised investments in the “Software” industry , 29.5% "Application Software" industry, 23.3% comprised investments in the “Drug "Drug Discovery & Development" industry,18.8% comprised investments in the "Healthcare Services, Other" industry, 10.6% in the "System Software" industry, and 10.1% comprised investments in the "Consumer & Business Services" industry.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, the current U.S. political environment and the new incoming U.S. federal administration and the resulting uncertainties regarding actual and potential shifts in U.S. foreign investment, trade, healthcare, taxation, economic, environmental and other policies, as well as the impact of geopolitical tension, such as a deterioration in the bilateral relationship between the U.S. and China or the conflict between Russia and Ukraine or conflict in the Middle East, could lead to disruption, instability and volatility in the global capital markets.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
(in thousands) December 31, 2024 2025 Fair Value Percentage of Net Assets Phathom Pharmaceuticals, Inc. $ 177,348 8.9% 182,883 8.3% Marathon Health, LLC 166,882 8.4% Axsome Therapeutics, 181,337 8.2% Armis, Inc. 165,220 8.3% 159,672 7.2% ChenMed, LLC 128,240 5.8% Shield AI, Inc. 113,701 5.7% 118,127 5.3% Tipalti Solutions Ltd. 113,467 5.1% SeatGeek, Inc. 110,413 5.5% Corium, Inc. 109,178 5.5% 111,031 5.0%
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
There currently is no active public trading market for the June 2025 Notes, June 2025 3-Year Notes, The March 2026 A Notes, March 2026 B Notes, September 2026 Notes, January 2027 Notes, 2028 Convertible Notes, June 2030 Notes, or 2031 Asset-Backed Notes. Notes may or may not have an active trading market.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
There is no If an active public trading market for the June 2025 Notes, June 2025 3-Year Notes, March 2026 A Notes, March 2026 B Notes, September 2026 Notes, January 2027 Notes, 2028 Convertible Notes, June 2030 Notes, or 2031 Asset-Backed Notes. Notes does not develop, holders could be unable to resell them.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Annual Return on Our Portfolio (Net of Expenses) -10% -5% (10%) (5%) 0% 5% 10% Corresponding return to common stockholder assuming our actual asset coverage of 231.7% 212.1% as of December 31, 2024(1) (23.77%) (14.14%) (4.51%) 5.12% 14.75% 2025(1) (25.94%) (15.59%) (5.25%) 5.09% 15.44% Corresponding return to common stockholder assuming 150% asset coverage(2) (42.32%) (26.52%) (10.72%) 5.08% 20.89% (42.46%) (26.62%) (10.78%) 5.06% 20.90%
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
However, as an internally managed BDC, our ability to offer more competitive and flexible compensation structures, structures is subject to the limitations imposed by the 1940 Act, such as limitations on offering both a profit-sharing plan and an equity incentive plan, is subject to the limitations imposed by the 1940 Act, which limits may limit our ability to attract and retain talented investment management professionals.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, under the terms of any credit facility or other debt instrument we enter into, in the event of a default, we are likely to be required by its terms to use the net proceeds of any investments that we sell to repay a portion of the amount borrowed under such facility or instrument before applying such net proceeds to any other uses.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Lenders of these senior securities will have fixed dollar claims on our assets that are superior to the claims of our common stockholders, and we would expect such lenders to seek recovery against our assets in the event of a default.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
We could experience fluctuations in our operating results due to a number of factors, including our ability or inability to make investments in companies that meet our investment criteria, the interest rate payable on the debt securities we acquire, the level of portfolio dividend and fee income, the level of our expenses, variations in and the timing of the recognition of realized and unrealized gains or losses, the degree to which we encounter competition in our markets and general economic conditions.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our secured credit facilities with Sumitomo Mitsui Banking Corporation (the “SMBC Facility”) and MUFG Union Bank, N.A., Ltd., (the “MUFG Bank Facility”) and our letter of credit facility with Sumitomo Mitsui Banking Corporation (the “SMBC LC Facility” and together with the SMBC Facility and MUFG Bank Facility, our “Credit Facilities”), as well as the February 2025 Notes, June 2025 Notes, June 2025 3-Year Notes, March 2026 A Notes, March 2026 B Notes, September 2026 Notes, January 2027 Notes, 2028 Convertible Notes, June 2030 Notes, 2031 Asset-Backed Notes and 2033 Notes (each term as is individually defined under “Note 5 - Debt” and collectively, the “Notes”), each outstanding as of December 31, 2024, 2025, contain financial and operating covenants that could restrict our business activities, including our ability to declare dividend distributions if we default under certain provisions.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our ability to recapitalize, incur additional debt and take a number of other actions that are not limited by the terms of the 2033 Notes, September 2026 Notes, January 2027 Notes, 2028 Convertible Notes and January 2027 June 2030 Notes may have important consequences for their holders, including making it more difficult for us to satisfy our obligations with respect to the 2033 Notes, September 2026 Notes, January 2027 Notes, 2028 Convertible Notes and January 2027 June 2030 Notes or negatively affecting their trading value.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We may seek puts or similar rights to give us the right to sell our equity securities back to the portfolio company issuer; however, we may not be unable able to exercise these put rights for the consideration provided in our investment documents if the issuer is in financial distress.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Because certain of our senior securities have customary cross-default and cross-acceleration provisions, if the indebtedness under our senior securities is accelerated, we may not be unable able to repay or finance the amounts due.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We may also may, however, seek such authorization at future annual or special meetings of stockholders.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
Net acceleration of loan discounts and loan fees due to early payoffs or restructures (13.6) (12.3)
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
(1)Effective December 31, 2025, the former “Software” category has been separated into “Application Software” and “System Software”. Prior year amounts have been reclassified to conform to the current presentation.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
within the reporting period; and (ii) $96.2 million of unfunded commitments which represent the portion of portfolio company commitments assigned to or directly committed by the Adviser Funds.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RemovedMD&A
(in millions) December 31, 2024 December 31, 2023 Beginning Portfolio $ 3,248.0 $ 2,963.9 New fundings and restructures 1,807.2 1,598.6 Fundings assigned to or directly funded by the Adviser Funds (383.2) (350.7) Warrants not related to current period fundings 0.3 1.3 Principal repayments received on investments (31.6) (50.8) Early payoffs (922.0) (925.1) Proceeds from sale of debt investments — (26.7) Proceeds from sale of equity and warrant investments (49.4) (43.2) Accretion of loan discounts and paid-in-kind interest 87.7 59.5 Net acceleration of loan discounts and loan fees due to early payoffs or restructures (12.3) (14.1) New loan fees (15.2) (13.5) Gain (loss) on investments due to sales or write offs (19.7) 6.0 Net change in unrealized appreciation (depreciation) (49.8) 42.8 Ending Portfolio $ 3,660.0 $ 3,248.0
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedMD&A
2024 as compared to 2023, was attributable to increased usage of our Credit Facilities which are floating rate instruments and have higher borrowing rates.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedMD&A
of our equity and warrant positions in Palantir Technologies, TransMedics Group, Inc., Tarsus Pharmaceuticals, Inc., DoorDash, Inc., and TG Therapeutics, Inc.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RewordedMD&A
(in thousands) Year Ended December 31, 2025 2024 2023 Debt Equity, Warrants Total Debt Equity, Warrants Total and and Investment Funds(1) Funds(2) Investment Funds(1) Funds(2) Investment valuation appreciation (depreciation) $ (5,049) $ 14,891 $ 9,842 $ (45,718) $ (6,162) $ (51,880) $ 26,689 $ 26,401 $ 53,090 Reversal of prior period net changes in unrealized appreciation (depreciation) upon a realization event(2) event(1) 28,755 (4,301) 24,454 26,665 (23,655) 3,010 (6,556) (5,373) (11,929) Other net changes in unrealized appreciation (depreciation) (depreciation)(2) 12,697 (8,181) 4,516 (816) 18,477 17,661 (15,612) (539) (16,151) Net change in unrealized appreciation (depreciation) $ 36,403 $ 2,409 $ 38,812 $ (19,869) $ (11,340) $ (31,209) $ 4,521 $ 20,489 $ 25,010
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
The net realized losses were generated from a realized loss of $63.1 million from the write-off of our debt investments relating to Convoy, Inc., Gritstone Bio, Inc., Better Therapeutics, Inc., and Eigen Technologies Ltd., which are net of recovered collections of $55.5 million. $44.6 million of the write-off of our debt investments resulted in a reversal of unrealized depreciation previously reported as of December 31, 2023.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
(in The following table shows the amortized cost of our performing and non-accrual investments as of December 31, 2025 and December 31, 2024:(in millions) As of December 31, 2025 2024 2023 Amortized Cost Percentage of Total Portfolio at Amortized Cost Amortized Cost Percentage of Total Portfolio at Amortized Cost Performing $ 4,457 99.8% $ 3,648 98.3% $ 3,216 99.0% Non-accrual 11 0.2% 61 1.7% 31 1.0% Total Investments $ 4,468 100.0% $ 3,709 100.0% $ 3,247 100.0%
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
(in A summary of net realized gains and losses for the years ended December 31, 2025 and 2024 is as follows:(in thousands) Year Ended December 31, 2025 2024 2023 Realized gains $ 32,096 $ 39,676 $ 29,920 Realized losses (70,553) (70,175) (21,493) Realized foreign exchange gains (losses) (2,154) (987) 10 Realized loss on debt extinguishment of debt (184) (171) — Net realized gains (losses) $ (40,795) $ (31,657) $ 8,437
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
During We distributed dividends of $326.0 million compared to $303.5 million, during the year years ended December 31, 2025 and 2024, we distributed dividends of $303.5 million compared to $273.7 million during the year ended December 31, 2023. respectively.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
We also reduced During the usage of year ended December 31, 2025, our overnight offering and ATM program, which program provided (net of offering costs) approximately $204.4 million compared to $218.3 million down from $338.2 million, net proceeds received during the years year ended December 31, 2024 and 2023. 2024.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
Employee stock-based compensation totaled approximately $14.6 million for the year ended December 31, 2025, as compared to approximately $12.8 million for the year ended December 31, 2024, as compared to approximately $13.2 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
The available unfunded commitments excludes unfunded commitments (i) for which, with respect to a portfolio company's agreement, a milestone was achieved after the last day on which the portfolio company could have requested a drawdown funding to be completed within the reporting period; and (ii) $139.7 million of unfunded commitments which represent the portion of portfolio company commitments assigned to or directly committed by the Adviser Funds.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
(2)Included in (1)For the years ended December 31, 2025 and 2024, reversals of prior period net changes in unrealized appreciation (depreciation) are include $45.2 million and $44.6 million million, respectively, of reversed unrealized depreciation, related to the $57.7 million and $63.1 million million, respectively, of realized debt loss losses from the write-off of certain debt investments noted above.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
(2)Included in (1)For the years ended December 31, 2025 and 2024, reversals of prior period net changes in unrealized appreciation (depreciation) are include $45.2 million and $44.6 million million, respectively, of reversed unrealized depreciation, related to the $57.7 million and $63.1 million million, respectively, of realized debt loss losses from the write-off of certain debt investments noted above.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
As of December 31, 2024, 2025, we had $658.8 $525.5 million in available liquidity, including $113.1 $57.0 million in cash, cash equivalents and foreign cash, and available borrowing capacity of approximately $16.2 $21.5 million (net of $0.5 million of outstanding letter of credits) under the SMBC Facility, $175.0 million under our SMBC letter of credit facility, $284.0 and $272.0 million under the MUFG Bank Facility, and $71.0 million of SBA debentures, subject to certain conditions.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in expenses allocated to the Adviser Subsidiary for the year ended December 31, 2024 2025 compared to 2023 2024 is due to higher average assets under management an increase in time spent on the Adviser Funds and higher allocations an increase in investments allocated to the Adviser Funds.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new